Galactooligosyllactose Inhibits Enterococcus faecalis Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Enterococcus faecalis, a Gram-positive bacterium, is increasingly resistant to antibiotics, particularly vancomycin, leading to serious hospital-acquired infections and reinfected root canal-treated teeth, with existing treatments failing to effectively manage its pathogenicity.
Innovation Solution
The use of specific galactooligosaccharides, such as 3'-galactosyllactose, 4'-galactosyllactose, and 6'-galactosyllactose, which are administered orally or intranasally, to inhibit the growth and abundance of Enterococcus faecalis in the gut, thereby preventing systemic infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antimicrobial agents are used to treat E. faecalis infections, then infections can be treated, but the bacteria develop resistance leading to treatment failure
Solution Approach 1:
The patent introduces galactooligosaccharides as an intermediary substance that mediates the interaction between the host and E. faecalis. These oligosaccharides do not directly kill the bacteria but rather prevent their adhesion to intestinal epithelium and inhibit their growth, thereby treating infections without selecting for antibiotic resistance. The oligosaccharides act as a protective intermediary that blocks bacterial pathogenicity.
Solution Approach 2:
The patent replaces the mechanical/chemical action of antibiotics (which directly target and kill bacteria, creating resistance pressure) with a biological mechanism involving galactooligosaccharides that prevent bacterial adhesion and growth through molecular recognition and interaction with intestinal epithelium. This substitution eliminates the selection pressure for resistance while maintaining therapeutic effectiveness.
2Reliability
If antibiotics are used to reduce E. faecalis abundance, then infection is treated, but the gut microbiome diversity is reduced
Solution Approach 1:
Galactooligosaccharides serve as a selective intermediary that specifically targets E. faecalis adhesion to intestinal epithelium without affecting other gut bacteria. By blocking the bacterial adhesion mechanism through molecular recognition, the oligosaccharides selectively reduce E. faecalis abundance while preserving the diversity and composition of the broader gut microbiome, thus treating infection without disrupting microbial ecology.
Solution Approach 2:
The patent applies local quality by targeting a specific function (adhesion to intestinal epithelium) rather than applying a broad-spectrum action. The galactooligosaccharides specifically interfere with E. faecalis adhesion mechanisms at the intestinal surface, providing localized treatment effect that spares other microbiome members and maintains overall microbial diversity and stability.
3Reliability
If vancomycin is used to treat E. faecalis, then resistant strains are targeted, but the bacteria become increasingly resistant
Solution Approach 1:
The patent substitutes the antibiotic mechanism (vancomycin binding to cell wall precursors) with a non-antibiotic mechanism involving galactooligosaccharides that prevent bacterial adhesion and growth through molecular recognition with intestinal epithelium. This substitution eliminates the selective pressure for vancomycin resistance while maintaining effectiveness against E. faecalis, including resistant strains.
Solution Approach 2:
The galactooligosaccharides act as a protective intermediary that blocks the interaction between E. faecalis and the intestinal environment, preventing colonization and infection without directly targeting the bacteria with antimicrobial agents. This intermediary mechanism avoids the evolution of resistance while effectively treating infections caused by vancomycin-resistant strains.
Data Source
AI summary
The invention relates to a preparation comprising 3'-galactosyllactose, 4'-galactosyllactose, and/or 6'-galactosyllactose for use in the treatment and prevention of a pathogenic Enterococcus faecalis infection in a subject. It was found that these compounds - in contrast to fructooligosaccharides and the human milk oligosaccharides 2'-FL, LNT, and LNnT - are able to reduce the abundance of Enterococcus faecalis in the microbiota. By inhibiting (out-)growth of E. faecalis in the gut, infections in other locations of the body can be prevented.